Skip to main content

European Training Network on Antiviral Drug Development

Objective

Viral infections are a major cause of disease, mortality and economic losses worldwide. Antiviral therapy is an essential instrument to control virus infections. At present, however, licensed antiviral drugs have been developed only against a limited number of viruses (e.g. HIV, HCV, influenza, herpesviruses). There is a clear and unmet need for antiviral drugs to treat infections with other important human pathogens.

Europe needs well-trained experts with multidisciplinary skills to advance the antiviral drug development field. However, few, if any, European universities or research institutes have the ability to deliver an intersectoral training programme that covers the broad spectrum of disciplines important for antiviral drug development.

The ANTIVIRALS partnership has been established to fill this gap. It consists of six outstanding European academic partners and four industrial partners (two large R&D companies, of which one is specialized in antiviral drug discovery and development, and two SMEs), and two partner organisations (incl. one SME specialised in education). All partners are leaders in their field, ensuring state-of-the-art training possibilities, and their skills are highly complementary.

ANTIVIRALS aims to introduce 15 ESRs to state-of-the-art knowledge and technology applied in antiviral drug development through both local and network-wide training activities. Individual research projects, research training workshops and intersectoral secondments will be supplemented with complementary skills courses and dissemination activities to improve career development and perspectives. The industrial partners are actively involved in the entire programme and will organize an industry-oriented conference aimed at further bridging the gap between academia and industry.

Thus, ANTIVIRALS offers talented researchers a multidisciplinary and intersectoral training programme and prepares them for a future leading role in antiviral drug development in Europe.

Call for proposal

H2020-MSCA-ITN-2014
See other projects for this call

Funding Scheme

MSCA-ITN-ETN - European Training Networks

Coordinator

UNIVERSITEIT UTRECHT
Address
Heidelberglaan 8
3584 CS Utrecht
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 510 748,56

Participants (11)

ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 510 748,56
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
UNIVERSITATSKLINIKUM HEIDELBERG
Germany
EU contribution
€ 498 432,96
Address
Im Neuenheimer Feld 672
69120 Heidelberg
Activity type
Higher or Secondary Education Establishments
CARDIFF UNIVERSITY
United Kingdom
EU contribution
€ 546 575,76
Address
Newport Road 30-36
CF24 ODE Cardiff
Activity type
Higher or Secondary Education Establishments
UNIVERSITE D'AIX MARSEILLE
France
EU contribution
€ 525 751,20
Address
Boulevard Charles Livon 58
13284 Marseille
Activity type
Higher or Secondary Education Establishments
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
EU contribution
€ 402 055,54
Address
Oude Markt 13
3000 Leuven
Activity type
Higher or Secondary Education Establishments
ARATANA THERAPEUTICS NV

Participation ended

Belgium
EU contribution
€ 0
Address
Ambachtenlaan 1
3001 Heverlee
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
AICURIS GMBH & CO. KG
Germany
EU contribution
€ 249 216,48
Address
Friedrich Ebert Str 475
42117 Wuppertal
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
COMPLIX NV

Participation ended

Belgium
EU contribution
€ 0
Address
Agoralaan Building A Bis Bioville
3590 Diepenbeek
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITAT WIEN
Austria
EU contribution
€ 244 061,58
Address
Universitatsring 1
1010 Wien
Activity type
Higher or Secondary Education Establishments
VIROVET
Belgium
EU contribution
€ 250 560
Address
Ambachtenlaan 1
3001 Leuven
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
COMPLIX LUXEMBOURG SA

Participation ended

Luxembourg
EU contribution
€ 99 063,77
Address
84 Val Fleuri
1526 Luxembourg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)

Partners (1)

Virology Education B.V.
Netherlands
Address
Biltstraat 106
3572 BJ Utrecht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)